Article Information
History
- July 2, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jenny G. Low, M.R.C.P., M.P.H.1,2,
- Ruklanthi de Alwis, M.P.H., Ph.D.2,
- Shiwei Chen, Ph.D.2,
- Shirin Kalimuddin, M.R.C.P., M.P.H.1,2,
- Yan Shan Leong, B.Sc.2,
- Tania Ken Lin Mah, B.Sc2,
- Natalene Yuen, B.Sc.2,3,
- Hwee Cheng Tan2,
- Summer L Zhang, M.Sc.2,
- Jean X.Y. Sim, M.R.C.P1,
- Yvonne F.Z. Chan, M.R.C.P.1,
- Ayesa Syenina, PhD.2,
- Jia Xin Yee, B.Sc.2,
- Eugenia Z. Ong, Ph.D.2,
- Rose Sekulovich, Ph.D.4,
- Brian B. Sullivan, Ph.D.4,
- Kelly Lindert, M.D.4,
- Sean B. Sullivan, Ph.D.4,
- Pad Chivukula, Ph.D.4,
- Steven G. Hughes, M.B.,B.S., M.B.A., F.R.C.P.4,* and
- Eng Eong. Ooi, B.M., B.S., Ph.D.2
- 1Singapore General Hospital
- 2Duke-National University of Singapore Medical School
- 3Nanyang Technological University
- 4Arcturus Therapeutics
- ↵*Correspondence to: Steven G Hughes, Arcturus Therapeutics, Inc., 10628 Science Center Drive, Suite 250, San Diego, CA92121, USA. Email: drstevehughes{at}gmail.com
Posted July 02, 2021.
A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults
